Kento Yokota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kento Yokota has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Daiki Nagira
Department of Respiratory Medicine Osaka General Medical Center Osaka Japan
2 shared publicationsMoto Yaga
Department of Respiratory Medicine Osaka General Medical Center Osaka Japan
2 shared publicationsSatoshi Tobita
Department of Respiratory Medicine Osaka General Medical Center Osaka Japan
2 shared publications- Takayuki Niitsu
Department of Respiratory Medicine Osaka General Medical Center Osaka Japan
2 shared publications Chika Takahashi
Department of Respiratory Medicine Osaka General Medical Center Osaka Japan
1 shared publicationKiyonobu Ueno
Department of Respiratory Medicine Osaka General Medical Center Osaka Japan
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (7) , e70674
Renewed Response to Pembrolizumab After Salvage Radiotherapy for Oligoprogression in Advanced NSCLC : A Case Report
Immune checkpoint inhibitor (ICI) rechallenge may benefit selected patients with NSCLC, but the role of local radiotherapy for oligoprogression and late same‐agent rechallenge remains uncertain. We report a patient with Stage IVA lung adenocarcinoma and a programmed death‐ligand 1 tumour proportion score of ≥ 75% who achieved a durable partial response to first‐line pembrolizumab. After isolated left supraclavicular nodal oligoprogression in 2020, he received salvage radiotherapy and remained off systemic treatment for almost 5 years. In late 2025, multiple new right lower lobe nodules and pleural‐based lesions appeared near the original primary site and enlarged on serial CT, prompting pembrolizumab rechallenge. CT in February 2026 showed a renewed partial response. This case suggests that rechallenge with pembrolizumab may remain reasonable at late relapse in carefully selected patients with durable initial benefit, limited progression controlled locally, a long treatment‐free interval, and good performance status.
- 14 July 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (7) , e70674
Open AccessRenewed Response to Pembrolizumab After Salvage Radiotherapy for Oligoprogression in Advanced NSCLC : A Case Report
Immune checkpoint inhibitor (ICI) rechallenge may benefit selected patients with NSCLC, but the role of local radiotherapy for oligoprogression and late same‐agent rechallenge remains uncertain. We report a patient with Stage IVA lung adenocarcinoma and a programmed death‐ligand 1 tumour proportion score of ≥ 75% who achieved a durable partial response to first‐line pembrolizumab. After isolated left supraclavicular nodal oligoprogression in 2020, he received salvage radiotherapy and remained off systemic treatment for almost 5 years. In late 2025, multiple new right lower lobe nodules and pleural‐based lesions appeared near the original primary site and enlarged on serial CT, prompting pembrolizumab rechallenge. CT in February 2026 showed a renewed partial response. This case suggests that rechallenge with pembrolizumab may remain reasonable at late relapse in carefully selected patients with durable initial benefit, limited progression controlled locally, a long treatment‐free interval, and good performance status.
- Open Access
- 16 December 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (12)
Endobronchial Watanabe Spigot for Acute Empyema With Bronchopleural Fistula: A Case Series
Empyema with bronchopleural fistula (BPF), defined by persistent air leak with pleural infection, undermines negative‐pressure drainage and often leads to highly invasive procedures such as fenestration. While endobronchial Watanabe spigots (EWSs) have mainly been used for postoperative or chronic fistulas, their role as an early intervention in acute infectious empyema with BPF remains uncertain. We report three consecutive frail patients with acute empyema and persistent air leak due to BPF treated using a prospectively predefined early EWS approach. After adequate drainage and antibiotics failed to seal the fistula, endobronchial occlusion was performed at the earliest bronchoscopic opportunity before considering fenestration. In all cases, EWS placement achieved complete cessation of air leak, allowed chest tube removal within 6–26 days and obviated fenestration. Diverse microbiology, including polymicrobial infection and nontuberculous mycobacteria, was controlled without observed device‐related infection or migration. Early EWS may offer a minimally invasive, fenestration‐sparing option in selected patients.
- 16 December 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (12)
Open AccessEndobronchial Watanabe Spigot for Acute Empyema With Bronchopleural Fistula: A Case Series
Empyema with bronchopleural fistula (BPF), defined by persistent air leak with pleural infection, undermines negative‐pressure drainage and often leads to highly invasive procedures such as fenestration. While endobronchial Watanabe spigots (EWSs) have mainly been used for postoperative or chronic fistulas, their role as an early intervention in acute infectious empyema with BPF remains uncertain. We report three consecutive frail patients with acute empyema and persistent air leak due to BPF treated using a prospectively predefined early EWS approach. After adequate drainage and antibiotics failed to seal the fistula, endobronchial occlusion was performed at the earliest bronchoscopic opportunity before considering fenestration. In all cases, EWS placement achieved complete cessation of air leak, allowed chest tube removal within 6–26 days and obviated fenestration. Diverse microbiology, including polymicrobial infection and nontuberculous mycobacteria, was controlled without observed device‐related infection or migration. Early EWS may offer a minimally invasive, fenestration‐sparing option in selected patients.